VERONA PHARMA P/S (NASDAQ:VRNA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Wednesday, Zacks.com reports. The brokerage currently has a $7.00 price objective on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 14.75% from the company’s current price.
According to Zacks, “Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom. “
Separately, Wedbush set a $56.00 target price on VERONA PHARMA P/S and gave the stock a “buy” rating in a report on Thursday, December 27th.
VERONA PHARMA P/S (NASDAQ:VRNA) last announced its earnings results on Tuesday, February 26th. The company reported ($0.28) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.15. As a group, equities research analysts anticipate that VERONA PHARMA P/S will post -2.26 EPS for the current fiscal year.
An institutional investor recently bought a new position in VERONA PHARMA P/S stock. Aisling Capital Management LP purchased a new stake in shares of VERONA PHARMA P/S (NASDAQ:VRNA) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 443,596 shares of the company’s stock, valued at approximately $4,281,000. VERONA PHARMA P/S accounts for about 4.5% of Aisling Capital Management LP’s portfolio, making the stock its 9th biggest position. Aisling Capital Management LP owned approximately 3.38% of VERONA PHARMA P/S as of its most recent SEC filing. 57.41% of the stock is currently owned by institutional investors.
VERONA PHARMA P/S Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.